Mallinckrodt (MNK) Announces Presentation of OFIRMEV Injection PK Data at Annual PMM of ASRA Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Futures climb as Alphabet, Microsoft results lift megacaps
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- Alphabet, Microsoft and Snap rise premarket; Intel, Hertz Global fall
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
Clinical Pharmacokinetic and Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 15th Annual Pain Medicine Meeting of ASRA
November 18, 2016 7:30 AM ESTCHESTERFIELD, United Kingdom, Nov. 18, 2016 /PRNewswire/ --Â Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, today announced results from a clinical pharmacokinetic (PK) study examining the effect of IV morphine on the absorption of orally administered acetaminophen.
The company also revealed findings from three retrospective claims-based analyses providing... More
